2018
DOI: 10.1111/jnc.14468
|View full text |Cite
|
Sign up to set email alerts
|

Subventricular zone lipidomic architecture loss in Huntington's disease

Abstract: The human subventricular zone (SVZ) has a defined cytological and neurochemical architecture, with four constituent laminae that act in concert to support its neurogenic activity. Lipidomic specialisation has previously been demonstrated in the neurologically normal human SVZ, with enrichment of functionally important lipid classes in each lamina. The SVZ is also responsive to neurodegenerative disorders, where thickening of the niche and enhanced proliferation of resident cells were observed in Huntington's d… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
31
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 36 publications
(31 citation statements)
references
References 95 publications
0
31
0
Order By: Relevance
“…160 CAG repeats [231]. The altered sphingolipid metabolism has also been noted in a variety of other cellular and animal HD models [226], although the changes seem to be less clearly weighted towards cell death than in, e.g., AD [228]. However, the reduced S1P levels observed in R6/2 mice [226] appear to be a relevant potential therapeutic target, as FTY720 has been demonstrated to improve neuronal activity, reduce brain atrophy, improve motor function, and increase R6/2 animal survival [232].…”
Section: Sphingolipids In Huntington’s Disease and Amyotrophic Lateramentioning
confidence: 99%
“…160 CAG repeats [231]. The altered sphingolipid metabolism has also been noted in a variety of other cellular and animal HD models [226], although the changes seem to be less clearly weighted towards cell death than in, e.g., AD [228]. However, the reduced S1P levels observed in R6/2 mice [226] appear to be a relevant potential therapeutic target, as FTY720 has been demonstrated to improve neuronal activity, reduce brain atrophy, improve motor function, and increase R6/2 animal survival [232].…”
Section: Sphingolipids In Huntington’s Disease and Amyotrophic Lateramentioning
confidence: 99%
“…Finally, an altered glycolipid metabolism was also detected in the AD brain samples [151]. Furthermore, MALDI imaging was used to elucidate alterations in the lipid architecture of brains from patients with Huntington disease [152].…”
Section: Which Matrix Fits Which Lipid Class?mentioning
confidence: 99%
“…Mounting evidence points to different roles for C1P in the nervous system. A 5-fold increase in C1P levels in the subventricular zone in Huntington disease patients has been reported, with no associated changes in Cer levels; this increase might represent a response to the chronic brain damage in these patients and might either reflect an attempt at neuroprotection and enhanced neurogenesis or contribute to neuroinflammation and neurodegeneration (Hunter et al, 2018). C1P has neuroprotective effects in the nervous system.…”
Section: Searching For Ceramide-1-phosphate Functions In the Retinamentioning
confidence: 99%